Search Results for "Ranbaxy Launches Atorvastatin In Us"

07:21 EST 29th November 2015 | BioPortfolio

Matching Channels


Matching News

Atorvastatin/Ezetimibe beats atorvastatin after PCI

(HealthDay)—For Japanese patients who have undergone percutaneous coronary intervention (PCI), atorvastatin plus ezetimibe is associated with improved outcomes versus atorvastatin alone, according t...

Sun Pharma sacks 18 Ranbaxy executives

Sun Pharma has asked 18 executives to leave the company who were previously a part of Ranbaxy, the firm it acquired last year.  This huge India-based restructuring move reflects one of the bigges...

A so-long wave to Tipperary? Sun earmarks Ranbaxy Ireland plant for sale

Sun Pharmaceutical has earmarked the Ranbaxy plant in Cashel in County Tipperary, Ireland for divestiture.

India's Sun Pharma misses profit estimates on Ranbaxy costs

MUMBAI, May 29 (Reuters) - Sun Pharmaceutical Industries Ltd , India's largest drugmaker by sales, reported fourth-quarter profit well below analysts' expectations, hit by costs related to integrating...

Sun Profit Dives On Ranbaxy Merger Costs

Sun Pharmaceutical Industries, India’s biggest drug maker by sales, has reported a 30% drop in quarterly net profit from a year earlier, undershooting analysts’ expectations for a third straight t...

Hand-Foot Syndrome Prevention With Atorvastatin, Polyprenol

Breast cancer patients receiving capecitabine had a lower incidence of hand-foot syndrome after prophylactic treatment with atorvastatin and polyprenol. Medscape Medical News

BRIEF-India's Sun Pharma says Strides Arcolab to buy some Ranbaxy businesses

* India's Sun Pharma says Strides Arcolab acquires CNS (central nervous system) divisions of erstwhile Ranbaxy

India's Sun Pharma expects Ranbaxy costs to hit 2016 revenue

MUMBAI, July 20 (Reuters) - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said on Monday its fiscal 2016 revenue might decline or stay flat due to costs related to fixing manu...

Matching PubMed Articles

Lipid-lowering efficacy of atorvastatin.

This represents the first update of this review, which was published in 2012. Atorvastatin is one of the most widely prescribed drugs and the most widely prescribed statin in the world. It is therefor...

Paradoxical effects of atorvastatin on renal tubular cells: an experimental investigation.

Atorvastatin has antioxidant activity and has been reported to increase blood antioxidant capacity. This study aimed to evaluate the effect of different doses of atorvastatin on gentamicin-induced kid...

Quercetin does not alter the oral bioavailability of Atorvastatin in rats.

The study was undertaken to evaluate the effect of Quercetin on the pharmacokinetics of Atorvastatin Calcium. In-vivo Pharmacokinetic studies were performed on rats in a single dose study and multiple...

Impact of low dose atorvastatin on development of new-onset diabetes mellitus in Asian population: Three-year clinical outcomes.

High dose atorvastatin is known to be associated with new onset diabetes mellitus (NODM) in patients with high risk for developing diabetes mellitus (DM). However, low dose atorvastatin is more common...

Physiologically Based Pharmacokinetic Modeling of Disposition and Drug-Drug Interactions for Atorvastatin and its Metabolites.

Atorvastatin is the most commonly used of all statins to lower cholesterol. Atorvastatin is extensively metabolized in both gut and liver to produce several active metabolites. The purpose of the pres...

Search Whole site using Google


Advertisement Advertisement